Loading...
XNYS
RVTY
Market cap16bUSD
Oct 08, Last price  
152.16USD
1D
-0.94%
1Q
35.51%
Jan 2017
191.77%
Name

Perkinelmer Inc

Chart & performance

D1W1MN
XNYS:RVTY chart
P/E
70.24
P/S
5.94
EPS
2.17
Div yield, %
0.18%
Shrs. gr., 5y
0.20%
Rev. gr., 5y
-5.47%
Revenues
2.86b
+3.67%
1,546,358,0001,787,331,0001,959,991,0001,550,766,0001,704,346,0001,921,287,0002,115,205,0002,166,232,0002,237,219,0002,104,822,9992,115,516,9992,256,982,0002,777,996,0002,883,673,0003,782,745,0003,827,808,0003,311,822,0002,750,571,0002,755,026,0002,856,051,000
Net income
242m
-18.31%
117,150,000132,918,000128,406,00085,599,000383,919,0001,172,00068,441,000167,924,000158,038,000212,453,000233,680,000113,018,000238,786,000227,558,000728,098,000943,157,000569,179,000-118,378,000295,833,000241,675,000
CFO
582m
-7.40%
127,440,000205,127,000217,844,000148,722,000164,253,000224,874,000152,170,000158,591,000281,597,000287,098,000350,615,000288,453,000311,038,000363,469,000892,177,0001,410,750,000679,810,00091,272,000628,299,000581,777,000
Dividend
Oct 23, 20260.07 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

PerkinElmer, Inc. operates as a global enterprise delivering innovative products, specialized services, and comprehensive solutions across the diagnostics, life sciences, and applied technology sectors. The company's operations are divided into two main segments: Discovery & Analytical Solutions, and Diagnostics. The Discovery & Analytical Solutions division furnishes scientists with an extensive suite of offerings, including chemical reagents, informatics platforms, and cutting-edge detection and imaging technologies. These resources are designed to accelerate research breakthroughs in the life sciences, and the segment also provides contract research and laboratory services. Additionally, it supplies analytical technologies, integrated solutions, and expert services to clients in the environmental, food, and industrial markets, aiding in the assessment and characterization of air, water, and soil quality. This segment further supports agricultural producers and food manufacturers, and delivers analytical instrumentation to a broad spectrum of industrial clients, encompassing chemical, semiconductor, electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment specializes in providing essential instruments, reagents, assay platforms, and software products for the early identification of genetic disorders, particularly during pregnancy and early childhood, as well as for infectious disease screening. Its product range facilitates the testing and detection of various genetic abnormalities and conditions, such as Down syndrome, hypothyroidism, muscular dystrophy, infertility, and diverse metabolic disorders. Moreover, this segment develops enabling technologies that support advanced genomic workflows, leveraging methods like G-protein coupled receptor (GPCR) analysis and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery research. PerkinElmer's client base is diverse, including pharmaceutical and biotechnology companies, research laboratories, academic and scientific institutions, public health organizations, private healthcare providers, medical professionals, and governmental agencies. Founded in 1937, PerkinElmer, Inc. is headquartered in Waltham, Massachusetts.

Related entities

Subsidiaries (2)
BIOSENSE TECHNOLOGIES PRIVATE LIMITED
EUROIMMUN Medizinische Labordiagnostika AG

Key people

Chief Financial Officer, Senior Vice President · since 2018
Chief Human Resource Officer, Senior Vice President · since 2016
James L. Corbett
Chief Financial Officer, Senior Vice President · since 2018
Daniel R. Tereau
Senior Vice President, Strategy and Business Development · since 2016
Tajinder S. Vohra
Senior Vice President, Global Operations · since 2015
Andrew Okun
Chief Accounting Officer, Vice President · since 2011
Joel S. Goldberg
Senior Vice President - Administration, General Counsel, Secretary · since 2008
Independent Director · since 2012
Independent Director · since 2016
Independent Non-Executive Chairman of the Board · since 2019
Independent Director · since 2016
Pascale Witz
Independent Director · since 2017
IPO date
Jul 06, 1965
Employees
11,000
Domiciled in
US
Incorporated in
US
Legal address
C/O C T CORPORATION SYSTEM
155 FEDERAL ST.
SUITE 700
BOSTON, MA 02110
US
Headquarters
77 4TH AVENUE
WALTHAM, MA 02451-7567
US
Previous name
EDGERTON, GERMESHAUSEN & GRIER, INC.
Previous name
EG&G, INC.
Previous name
PERKINELMER, INC.

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT